Unani treatment for menstrual problem

Effect of JawÄ?rish-i-qurá¹um on Premenstrual Syndrome â?? A Randomized Controlled Study.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040146

Enrollment

Registered

2022-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N943- Premenstrual tension syndrome

Interventions

Intervention1: JawÄ?rish-i-qurá¹um: 5gm of JawÄ?rish-i-qurá¹um BD orally for 7 days per cycle for 3 consecutive cycles. Control Intervention1: Placebo: Placebo (Mixture of wheat flour and white suga

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age within the range of 15 â?? 40years 2.Regular menstrual cycle 21 â?? 35 days presenting with sign and symptoms of premenstrual syndrome. 3.Presenting with marked relief of symptoms at onset of menses. 4.Sign and symptoms of PMS at least 3 cycles as per ACOG guidelines

Exclusion criteria

Exclusion criteria: .Irregular cycles 2.Pelvic pathology having huge fibroid/cyst. 3.On OCPs and lactating mothers. 4.Systemic, metabolic and endocrine disease. 5.K/C/O Psychological illnesses and seizures disorders.

Design outcomes

Primary

Measure	Time frame
Change in Anxiety, Irritability, Depression, Headache, Confusion, Insomnia, Mood swings, Fatigue, Backache, Menstrual Cramps.Timepoint: after every cycle , Pre & Post test	—

Secondary

Measure	Time frame
Change in Premenstrual Syndrome Scale (PMSS) and For QoL Sheehanâ??s Disability Scale (SDS).Timepoint: after every cycle and pre & post test	—

Countries

India

Contacts

Public ContactProf Dr Wajeeha Begum

National Institute Of Unani Medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026